公开(公告)号：US11471406B2

公开(公告)日：2022-10-18

申请号：US17063644

申请日：2020-10-05

申请人： INTELGENX CORP.

发明人： Nadine Paiement ,  Rodolphe Obeid ,  Justin Conway ,  Billal Tir

IPC分类号： A61K9/00 ,  A61K47/38 ,  A61K31/4985

摘要： An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.

公开(公告)号：US20190290595A1

公开(公告)日：2019-09-26

申请号：US16441872

申请日：2019-06-14

申请人： Intelgenx Corp.

发明人： Horst G. Zerbe ,  Rodolphe Obeid ,  Justin W. Conway ,  Nadine Paiement ,  Ludwig Aigner

IPC分类号： A61K9/70 ,  A61K9/00 ,  A61K31/381 ,  A61K31/404 ,  A61K31/47

摘要： Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

公开(公告)号：US20180228738A1

公开(公告)日：2018-08-16

申请号：US15912103

申请日：2018-03-05

申请人： Intelgenx Corp.

发明人： Horst G. Zerbe ,  Rodolphe Obeid ,  Justin W. Conway ,  Nadine Paiement ,  Ludwig Aigner

IPC分类号： A61K9/70 ,  A61K31/47 ,  A61K31/381 ,  A61K31/404

摘要： Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

公开(公告)号：US20170258710A1

公开(公告)日：2017-09-14

申请号：US15067309

申请日：2016-03-11

申请人： Intelgenx Corp.

发明人： Justin Conway ,  Rodolphe Obeid ,  Nadine Paiement ,  Horst Zerbe

IPC分类号： A61K9/00 ,  A61K47/36 ,  A61K9/70 ,  A61K31/47

CPC分类号： A61K9/006 ,  A61K9/146 ,  A61K9/7007 ,  A61K31/47 ,  A61K47/32 ,  A61K47/36

摘要： An oral film product in which a pharmaceutically active agent is stabilized in its partially-ionized form to better facilitate oral transmucosal delivery is provided. The film includes a bioadhesive layer including a pharmaceutically active agent having a logarithmic acid dissociation constant that is less than 4.5 and which is complexed with a cationic polymer.

公开(公告)号：US20170239172A1

公开(公告)日：2017-08-24

申请号：US15588897

申请日：2017-05-08

申请人： Intelgenx Corp.

发明人： Rodolphe Obeid ,  Nadine Paiement

IPC分类号： A61K9/00 ,  A61K47/34 ,  A61K47/10 ,  A61K9/70

CPC分类号： A61K9/006 ,  A61K9/7007 ,  A61K45/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34

摘要： An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

公开(公告)号：US20170216220A1

公开(公告)日：2017-08-03

申请号：US15014269

申请日：2016-02-03

申请人： Intelgenx Corp.

发明人： Mobarik Bilal ,  Rodolphe Obeid ,  Nadine Paiement

IPC分类号： A61K9/70 ,  A61K9/00 ,  A61K47/28 ,  A61K47/02 ,  A61K47/10 ,  A61K47/36 ,  A61K31/553 ,  A61K47/32

CPC分类号： A61K9/7007 ,  A61K9/006 ,  A61K31/553 ,  A61K47/10 ,  A61K47/32 ,  A61K47/36

摘要： A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.

公开(公告)号：US20230248660A1

公开(公告)日：2023-08-10

申请号：US18125800

申请日：2023-03-24

申请人： Intelgenx Corp.

发明人： Mobarik Bilal ,  Rodolphe Obeid ,  Nadine Paiement

IPC分类号： A61K9/70 ,  A61K31/553 ,  A61K9/00 ,  A61K47/28 ,  A61K47/10 ,  A61K47/36 ,  A61K47/32 ,  A61K47/26 ,  A61K47/18 ,  A61K47/38

CPC分类号： A61K9/7015 ,  A61K31/553 ,  A61K9/006 ,  A61K47/28 ,  A61K47/10 ,  A61K47/36 ,  A61K47/32 ,  A61K47/26 ,  A61K47/186 ,  A61K9/7007 ,  A61K47/38

摘要： A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.

公开(公告)号：US20230047314A1

公开(公告)日：2023-02-16

申请号：US17952300

申请日：2022-09-25

申请人： INTELGENX CORP.

发明人： Nadine PAIEMENT ,  Rodolphe OBEID ,  Justin CONWAY ,  Billal TIR

IPC分类号： A61K9/00 ,  A61K47/38 ,  A61K31/4985

摘要： An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm

公开(公告)号：US20200215063A1

公开(公告)日：2020-07-09

申请号：US16820794

申请日：2020-03-17

申请人： Intelgenx Corp.

发明人： Horst G. Zerbe ,  Nadine Paiement ,  Angela Angusti ,  Cormac Long ,  Rodolphe Obeid ,  Laetitia Rodes ,  Billal Tir

IPC分类号： A61K31/4985 ,  A61K9/00 ,  A61K9/70

摘要： Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.

公开(公告)号：US20190247505A1

公开(公告)日：2019-08-15

申请号：US16391430

申请日：2019-04-23

申请人： Intelgenx Corp.

发明人： Nadine Paiement ,  Rodolphe Obeid ,  Billal Tir

IPC分类号： A61K47/10 ,  A61K9/70 ,  A61K31/196 ,  A61K31/5513 ,  A61K9/00 ,  A61K31/4985 ,  A61K31/7076 ,  A61K31/704 ,  A61K31/60 ,  A61K31/58 ,  A61K31/573 ,  A61K31/5517 ,  A61K31/415 ,  A61K31/40 ,  A61K31/216

CPC分类号： A61K47/10 ,  A61K9/006 ,  A61K9/7007 ,  A61K31/196 ,  A61K31/216 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4985 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/573 ,  A61K31/58 ,  A61K31/60 ,  A61K31/704 ,  A61K31/7076 ,  A61K38/00

摘要： Oral thin film dosage form of a stable dispersion of non-solubilized amorphous or partially amorphous active agent(s), having a mean particle size diameter D50 equal or less than 250 μm, that remains uniformly distributed within a film matrix and contains at least one film forming polymer, and optional pharmaceutically-acceptable excipients, such as diluents, plasticizers, surfactants, sweeteners, and taste-masking agent(s), are prepared by a process including first providing the active agent in an amorphous particle form having a mean particle size diameter D50 equal or less than 250 μm. Next, the active agent is suspended in a liquid film-forming formulation without dissolving the active agent. Therefore, the solvent is removed to form a film.